- Home
- FRD vs CRDL Comparison
FRD vs CRDL Comparison
Compare FRD & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- CRDL
- Stock Information
- Founded
- FRD 1965
- CRDL 2017
- Country
- FRD United States
- CRDL Canada
- Employees
- FRD N/A
- CRDL N/A
- Industry
- FRD Steel/Iron Ore
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRD Industrials
- CRDL Health Care
- Exchange
- FRD Nasdaq
- CRDL Nasdaq
- Market Cap
- FRD 122.0M
- CRDL 102.0M
- IPO Year
- FRD N/A
- CRDL N/A
- Fundamental
- Price
- FRD $17.00
- CRDL $0.99
- Analyst Decision
- FRD
- CRDL Strong Buy
- Analyst Count
- FRD 0
- CRDL 3
- Target Price
- FRD N/A
- CRDL $9.00
- AVG Volume (30 Days)
- FRD 24.4K
- CRDL 226.1K
- Earning Date
- FRD 06-10-2025
- CRDL 05-13-2025
- Dividend Yield
- FRD 0.94%
- CRDL N/A
- EPS Growth
- FRD N/A
- CRDL N/A
- EPS
- FRD 0.81
- CRDL N/A
- Revenue
- FRD $447,616,000.00
- CRDL N/A
- Revenue This Year
- FRD N/A
- CRDL N/A
- Revenue Next Year
- FRD N/A
- CRDL N/A
- P/E Ratio
- FRD $20.62
- CRDL N/A
- Revenue Growth
- FRD N/A
- CRDL N/A
- 52 Week Low
- FRD $12.24
- CRDL $0.77
- 52 Week High
- FRD $19.47
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- FRD 61.76
- CRDL 48.65
- Support Level
- FRD $14.26
- CRDL $0.92
- Resistance Level
- FRD $17.24
- CRDL $1.08
- Average True Range (ATR)
- FRD 1.02
- CRDL 0.11
- MACD
- FRD 0.31
- CRDL 0.02
- Stochastic Oscillator
- FRD 95.20
- CRDL 67.81
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.